NCT01743729 - A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye | Biotech Hunter

Enrollment

720

Participants

Timeline

Start Date

December 7, 2012

Primary Completion Date

October 1, 2013

Study Completion Date

October 1, 2013

Conditions

Dry Eye Disease

Interventions

DRUG

Lifitegrast

Lifitegrast Ophthalmic Solution 5.0%

DRUG

Placebo

Placebo for Lifitegrast Ophthalmic Solution 5.0%

Trial Locations (31)

10016

OPUS-2 Investigational Site, New York

10036

OPUS-2 Investigational Site, New York

11793

OPUS-2 Investigational Site, Wantagh

19148

OPUS-2 Investigational Site, Philadelphia

23502

OPUS-2 Investigational Site, Norfolk

33901

OPUS-2 Investigational Site, Fort Myers

40509

OPUS-2 Investigational Site, Lexington

44115

OPUS-2 Investigational Site, Cleveland

46260

OPUS-2 Investigational Site, Indianapolis

47150

OPUS-2 Investigational Site, New Albany

55082

OPUS-2 Investigational Site, Saint Paul

60169

OPUS-2 Investigational Site, Hoffman Estates

63017

OPUS-2 Investigational Site, Chesterfield

63090

OPUS-2 Investigational Site, Washington

63131

OPUS-2 Investigational Site, Des Peres

64055

OPUS-2 Investigational Site, Independence

64111

OPUS-2 Investigational Site, Kansas City

77034

OPUS-2 Investigational Site, Houston

77055

OPUS-2 Investigational Site, Houston

77573

OPUS-2 Investigational Site, League City

78209

OPUS-2 Investigational Site, San Antonio

78229

OPUS-2 Investigational Site, San Antonio

90640

OPUS-2 Investigational Site, Montebello

90701

OPUS-2 Investigational Site, Artesia

91345

OPUS-2 Investigational Site, Mission Hills

92545

OPUS-2 Investigational Site, Hemet

92663

OPUS-2 Investigational Site, Newport Beach

93534

OPUS-2 Investigational Site, Lancaster

94954

OPUS-2 Investigational Site, Petaluma

95670

OPUS-2 Investigational SIte, Rancho Cordova

06810

OPUS-2 Investigational Site, Danbury